



## GeneTether Therapeutics Inc. Files Amended and Restated Preliminary Prospectus for Initial Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

**Vancouver, British Columbia – February 2, 2022** – GeneTether Therapeutics Inc., an EGB Ventures portfolio company (“**GeneTether**” or the “**Company**”), announces that it has filed an amended and restated preliminary prospectus (the “**Amended Preliminary Prospectus**”) for a proposed initial public offering (the “**Offering**”) of units of the Company (the “**Units**”) for minimum gross proceeds of \$4,500,000. The Company obtained a receipt for the Amended Preliminary Prospectus with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario.

GeneTether’s disruptive proprietary platform technology is focused on highly efficient insertion of DNA into the genome for gene correction and complementation strategies. The Company is developing curative therapies for the treatment of rare genetic diseases, supported by its wholly-owned intellectual property portfolio. GeneTether’s proof of concept study demonstrated that GeneTether’s proprietary technology resulted in an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTether’s technology.

The offering price per Unit will be determined by negotiation between the Company and Research Capital Corporation (the “**Agent**”) and is expected to be between \$0.60 and \$0.80 per Unit (the “**Offering Price**”). Each Unit consists of one common share of the Company (a “**Unit Share**”) and one common share purchase warrant of the Company (a “**Unit Warrant**”). Each Unit Warrant will entitle the holder, subject to the terms and conditions of a warrant indenture to be entered into on or prior to the closing of the Offering, to acquire one additional common share of the Company at a purchase price representing a 20% premium to the Offering Price for a period of 36 months following the closing date. The maximum size of the Offering will also be determined in the context of the market. The Offering is expected to close on or about February 23, 2022.

The Offering is being led by the Agent as the lead agent and sole bookrunner.

GeneTether has applied to list its common shares on the TSX Venture Exchange (“**TSXV**”). Listing is subject to the approval of the TSXV in accordance with its listing requirements.

The Amended Preliminary Prospectus contains important information relating to GeneTether and the Units and has been filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario. The Amended Preliminary Prospectus remains subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the Units until a receipt for the final prospectus has been issued by the relevant securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario. A copy of the Amended Preliminary Prospectus can be obtained under the Company’s corporate profile on

SEDAR at [www.sedar.com](http://www.sedar.com). There can be no assurance that the Company will satisfy all applicable requirements for listing its common shares on the TSXV and that its application for listing will be approved or that a receipt for its final prospectus will be issued.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any U.S. state securities law and may not be offered or sold in the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.

### **About GeneTether**

Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Company's wholly-owned platform technology uses a proprietary method to "tether" donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTether's proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTether's technology.

For more information, visit [www.genetether.com](http://www.genetether.com).

### **Contacts:**

Roland Boivin, CEO  
GeneTether Therapeutics Inc.  
(833) 294-4363 ext. 1  
[roland@genetether.com](mailto:roland@genetether.com)

Jean Jen, CFO  
GeneTether Therapeutics Inc.  
(833) 294-4363 ext. 2  
[jean@genetether.com](mailto:jean@genetether.com)

### **Forward-Looking Disclaimer**

*Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect,"*

*"is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information, including statements regarding the size of the Offering, the expected Offering Price and the timing for completion of the Offering. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.*

*Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by GeneTether as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of GeneTether's Amended Preliminary Prospectus available at [www.sedar.com](http://www.sedar.com). These factors are not intended to represent a complete list of the factors that could affect GeneTether; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and GeneTether expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.*

*Neither the TSXV nor its regulation services provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.*